Open AccessComplete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
Author(s) -
Ojemuyiwa Michelle,
Zeman Karen,
Spira Alexander,
Oronsky Bryan,
Ray Carolyn,
Trepel Jane B.,
Lee MinJung,
Onyiuke Ifeyinwa,
Brzezniak Christina
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1880
Subject(s) - medicine , prostate cancer , neuroendocrine carcinoma , oncology , chemotherapy , neuroendocrine tumors , cancer , carcinoma
Key Clinical Message Presented herein is the case of a heavily pretreated patient with high‐grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum‐based chemotherapy after treatment with the dual CD‐47 and SIRP‐α inhibitor, RRx‐001, in a Phase II clinical trial.